Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly lysosome and autophagy | 1.00 |
No case: the score is under the bar. Receipt 13843
Sealed predictions
- MAN2B2 in dopamine neurons, braak+0.18 (p 0.638) → -0.48 (p 0.186)receipt 13848
Swarm cases
receipt 13848: MAN2B2 in dopamine neurons, braak
- power
- full sample -0.16 (p 0.515, n 18), 95% CI -0.59 to +0.33. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.14 (p 0.579, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.21 (p 0.408, n 18). could be the mix.
- skeptic
- leave-one-out range -0.31 to -0.07, sign flips 0; without severely affected donors -0.16 (p 0.515, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.63 (p 0.0055, n 18) vs -0.16 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MAN2B2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MAN2B2 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.20 p 0.477 (needs p < 1.7e-4)
Receipts
loading the receipts